Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Akebia Therapeutics's average Book Value per Share Growth Rate was -17.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 63.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Akebia Therapeutics was 63.80% per year. The lowest was -79.50% per year. And the median was -13.40% per year.
Akebia Therapeutics (FRA:AX9) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Akebia Therapeutics 3-Year Book Growth Rate Related Terms
FRA:AX9 vs ORGO, SIGA, DERM: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's 3-Year Book Growth Rate falls into.
Akebia Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 63.80% mean?
Akebia Therapeutics (FRA:AX9) has a 3-Year Book Growth Rate of 63.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Akebia Therapeutics and its competitors. According to the industry distribution chart, Akebia Therapeutics ranks #31 out of 910 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is Akebia Therapeutics' 3-Year Book Growth Rate too high?
Akebia Therapeutics' current 3-Year Book Growth Rate is 63.80%. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Akebia Therapeutics' value of 63.80% is 1287% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #31 out of 910 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' 3-Year Book Growth Rate compare to ORGO and SIGA?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #31 out of 910 companies for 3-Year Book Growth Rate. This places Akebia Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.60. Akebia Therapeutics' value of 63.80% is 1287% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current 3-Year Book Growth Rate of 63.80% is 1287% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current 3-Year Book Growth Rate is 63.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.02, compared to a current price of €0.82 — trading 20.1% below its estimated fair value. The current 3-Year Book Growth Rate is 63.80% and 1287% above the Drug Manufacturers industry median of 4.60. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current 3-Year Book Growth Rate is 63.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.82 is trading 20.1% below its estimated GF Value™ of €1.02.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for FRA:AX9:
3-Year Book Growth Rate: 63.80%
GF Value™: €1.02 vs. price of €0.82 (20.1% below fair value)
Industry Position: 1287% above the Drug Manufacturers median (#31 of 910)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for FRA:AX9
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
